Event in Progress:
Discover the latest content that has just been published on Research Tree
AbbVie delivered a mixed result in the last quarter with revenues falling below analyst expectations. However, the company did manage an earnings beat. The management has focused on the rapid development and introduction of SKYRIZI and RINVOQ for all of HUMIRA's key indications as well as a brand-new indication, atopic dermatitis. By 2027, they predict that the combined sales of these two medications will surpass the peak revenues of HUMIRA, with a strong increase anticipated until the remainder
Companies: AbbVie (ABBV:NYSE)AbbVie, Inc. (ABBV:NYS)
Baptista Research
AbbVie's results for the past quarter were mixed and the company failed to meet Wall Street expectations with respect to its revenues but managed an earnings beat. With Skyrizi and Rinvoq currently on track to produce more than $7.5 billion in combined sales this year, significantly ahead of their initial projections, immunology once again exhibited a good performance. This outcome is particularly encouraging given that Rinvoq is being used to treat atopic dermatitis and IBD and PSA are still in
AbbVie has witnessed a strong correction over the past few months and its results have also not been the best. The company’s revenues in the last result were below market expectations though it did deliver an earnings beat. The silver lining for AbbVie has been the strong growth in double-digit operational sales from immunology, where Skyrizi exceeded the expectation of the company with its impressive market share gains in both PSA and psoriasis. The recent U.S approval of Skyrizi in Crohn’s dis
Companies: AbbVie, Inc. (ABBV:NYS)AbbVie, Inc. (0QCV:LON)
AbbVie had a positive start to 2022 with total net revenue and adjusted earnings exceeding the expectations of the management. The company is seeing positive momentum over various important portfolios and products, which include strong operational revenue growth from Aesthetics, Neuroscience, Rinvoq, and Skyrizi. Skyrizi has been performing particularly well for AbbVie. In psoriasis, the company has been achieving good profits and the recent launch of Skyrizi in psoriatic arthritis and the antic
AbbVie had a decent financial result with a balanced performance demonstrated across every major growth franchise, including a double-digit equivalent operation growth in revenue from neuroscience, aesthetics, and immunology. The management is expecting to add various innovative indications to the list of approved usages for Rinvoq and Skyrizi in 2022. The company has established a prominent position with Venclexta and Imbruvica in hematological oncology. The increased promotional investments of
AbbVie has received a number of interesting FDA approvals over the past months and are on track to be either approved or under review across all of Humira's primary indications. The company's Neuroscience division has seen excellent momentum off late. In addition, they experienced solid growth in their platforms, including aesthetics and hematological oncology portfolio. Based on our credit analysis, the company merits a Credit Evaluation Score of A with a stable outlook and as per our Financial
AbbVie has received an exciting set of FDA approvals over the past few weeks which have made the company’s stock soar. In the first week of December 2021, the company announced the approval of its Vuity 1.25% prescription eye drop, the first and only FDA-approved eye drop to treat presbyopia – age-related blurry vision. AbbVie also received approval for its Rinvoq (upadacitinib; 15 mg) medication to treat patients of active psoriatic arthritis. Apart from these big approval announcements which a
AbbVie has come very close to the target price from our last report as the company delivered an outstanding quarter with adjusted earnings per share of $3.11 well ahead of the management guidance coupled with a 19.3% top-line growth on a comparable operational basis. The recovery across the company portfolio is going very well in aggregate in specific disease areas such as CLL and HCV. The management expects that these specialty areas will further recover as the year progresses. AbbVie was recen
The cancer burden is growing globally. Each year >18 million people are diagnosed, nearly 10 million die and the estimated economic cost exceeds $1 trillion. From early diagnosis to late-stage disease, cancer care often involves inappropriate or unnecessary interventions that drive costs but provide limited clinical benefit. Coupled with an increased understanding of cancer biology and rapid technological advances, this has been driving momentum for precision medicine, leading to patient and soc
Companies: IMM IBAB 0O8G BCART 0QLR RHO5 MRCK 0QXH VSC 0QGJ SANO 0OCQ IPH GSK AZN 0Y6X QGEN 0HL9 0GRZ EJXB 0Q15 ABBV 0HAV 0RIH 0R0T BMYS EXK 0J8Z 0R29 0R34 0K3W NSTGQ 0KCC 0Q1N SGEN 0R0H 12V VNRX XE9
goetzpartners securities Limited
Research Tree provides access to ongoing research coverage, media content and regulatory news on AbbVie, Inc.. We currently have 0 research reports from 5 professional analysts.
Companies: BILN IGP RBN SBTX
Cavendish
Verici’s $8.2m gross raise means the company can now focus on scaling Tutivia and invest further into the development of existing and new products. With a uniquely well balanced Tutivia test, a growing sales team and LCD coverage expected later this year, we forecast Tutivia revenues of $2.6m/$4.5m in FY24E/FY25E. The Thermo Fisher deal was a huge validation of Clarava and Verici’s technology and in addition to licensing/milestone payments, we forecast double digit royalties on net Clarava sales
Companies: Verici Dx Plc
Singer Capital Markets
26th March 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object
Companies: BIRD MBH CHRT INSE KMK FNTL HDD JNEO CCS
Hybridan
Companies: Aptamer Group Plc
Turner Pope Investments
SkinBioTherapeutics has reported on the 6-months to December 2023, noting steady revenue growth from lead product AxisBiotix-Ps, progress on the development of SkinBiotix with partner Croda (Sederma) and post-period end, the acquisition of Dermatonics. The company has updated on several positive developments through the start of 2024, including AxisBiotix Acne positive interim results, initiation of research on the MediBiotix Pillar and progress with the oral and inflammation programmes. The com
Companies: SkinBioTherapeutics Plc
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (
Companies: TXG NDVA TSVT BCOW Z29 TXG NCYT GNS SUN AMS OMG APH EKF EAH IMM AGL DEMG AGY TSTL IPO GDR ETX TRX HVO CTEC AVO OXB DEST VLG IXI VAL INDV AGR AVCT BAI 123F IMCR BCOW
Hardman & Co
Companies: CLBS GHH NANO TRX SAVE TMT GELN
On 18th December 2023 Incanthera announced a deal with Marionnaud in Switzerland to distribute ‘Skin+CELL’, its advanced dermatological solution for the delivery of vitamin B3 for skin protection and cosmetic rejuvenation. This gives Incanthera access to a high-end cosmetics distribution presence in Europe, and in addition, ownership of Marionnaud by AS Watson, the largest cosmetics distributor in Asia, offers significant new market opportunities further afield.
Companies: Incanthera Plc
Stanford Capital Partners
FY EBITDA and EBIT came in materially above consensus FY EBITDA came in at EUR98.8m, down 4% yoy and 12% above consensus. The EBITDA margin was 12.6%. Restated for one-off costs, it was 13.1%, more than 2 percentage points above the guidance. It was fully explained by price increases, notably on X-ray, mix and control of fixed costs. FY EBITA came in at EUR38m, 46% above consensus. 2024 guidance looks conservative Guerbet is aiming for organic growth above 8% (8.8%e). With markets growing at
Companies: Guerbet (GBT:EPA)Guerbet SA (GBT:PAR)
BNP Paribas Exane - Sponsored Research
IRLAB Therapeutics has confirmed the FDA’s alignment with its proposed Phase III programme for mesdopetam in levodopa-induced dyskinesias (PD-LIDs), following receipt of the minutes from its end-of-Phase II (EoP2) meeting held last month. Notably, the FDA has agreed on the primary endpoint being the Unified Dyskinesia Rating Scale (UDysRS), on which mesdopetam demonstrated a statistically significant improvement (p=0.026) in the Phase IIb study (secondary endpoint of that study). IRLAB will now
Companies: Irlab Therapeutics Ab
Edison
Tissue Regenix has reported on strong performance through 2023, noting record revenues driven by product adoption and expanded distribution, positive adjusted EBITDA for the first time and an increased cash position versus H1/23. FY23 revenues grew 20% to $29.5m supported by 25% growth from BioRinse products and 17% growth from dCELL products. Significantly, Tissue Regenix reported its first adjusted EBITDA profit for the year, +$0.9m, supported by revenue growth and cost management. We expect t
Companies: Tissue Regenix Group plc
Creo Medical has published a trading update for the 12 months to December 2023, during which the company focused on commercialising its core technology. Revenue for the period increased 13% YoY to £30.8m, while the underlying operating loss improved to £16.4m. Operationally, during the period, the number of confirmed users of Creo’s Speedboat range more than doubled over the year, the first procedures with MicroBlate Flex to ablate lung tumours were performed and Creo expects to receive regulato
Companies: Creo Medical Group Plc
Companies: NTQ KMK JNEO DCTA
LungLife AI is a medical diagnostics company focused on the development of AI-supported blood-based tests for the early detection of lung cancer. It has identified a significant medical need for non-invasive, sensitive and specific tests in early-stage lung cancer. The company’s core technology, the LungLB test, seeks to detect circulating tumour cells (CTCs) to identify malignant lung nodules. It aims to apply machine learning/AI (ML/AI) to derive algorithms to increase test accuracy. Following
Companies: LungLife AI, Inc.
This month's feature article is entitled 'Gold and a Chinese Credit Event'. A Western phenomenon? If you own, or are considering owning, gold or gold equities, it’s likely that you’re concerned about protecting your wealth, or the performance of your fund, in the expectation of some kind of financial instability. Maybe your confidence in policymakers is ebbing, or you’ve researched debt bubbles in history and concluded that physical gold and silver have been the safest places to be invested whe
Companies: NBPE ICGT ARBB CSN RECI CLIG HAT AVO STX VTA APAX
Share: